

![]() |
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial |
|
Authors | ![]() | |
Published in | Clinical lung cancer. 2017, vol. 18, no. 3, p. 303-309 | |
Abstract | Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous non-small-cell lung cancer. It is currently unknown whether bevacizumab plus pemetrexed is superior to pemetrexed alone. | |
Keywords | Bevacizumab — Chemotherapy — Lung cancer — Maintenance therapy — Pemetrexed | |
Identifiers | PMID: 27993482 | |
Full text | ||
Structures | ||
Research groups | Cancer du poumon et mésothéliome pleural malin (944) Groupe Mach Nicolas (oncologie) (654) | |
Citation (ISO format) | GAUTSCHI, Oliver et al. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. In: Clinical lung cancer, 2017, vol. 18, n° 3, p. 303-309. doi: 10.1016/j.cllc.2016.11.007 https://archive-ouverte.unige.ch/unige:93754 |